Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
South Korea
· Delayed Price · Currency is KRW 41,100
+1,300 (3.27%)
Jun 19, 2025, 3:30 PM KST
Mezzion Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 8,407 | 8,612 | 31,721 | 30,726 | 26,654 | 28,634 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | - | - | - | Upgrade
|
| Revenue | 8,407 | 8,612 | 31,721 | 30,726 | 26,654 | 28,634 | Upgrade
|
| Revenue Growth (YoY) | -67.78% | -72.85% | 3.24% | 15.28% | -6.92% | 59.78% | Upgrade
|
| Cost of Revenue | 6,633 | 6,701 | 27,836 | 31,040 | 22,956 | 21,196 | Upgrade
|
| Gross Profit | 1,774 | 1,910 | 3,884 | -313.44 | 3,698 | 7,438 | Upgrade
|
| Selling, General & Admin | 14,265 | 14,958 | 16,142 | 19,510 | 17,283 | 12,857 | Upgrade
|
| Research & Development | 294.04 | 294.04 | 938.97 | 2,217 | 1,956 | 937.56 | Upgrade
|
| Operating Expenses | 15,525 | 16,210 | 18,373 | 23,018 | 20,496 | 14,969 | Upgrade
|
| Operating Income | -13,752 | -14,300 | -14,489 | -23,331 | -16,798 | -7,531 | Upgrade
|
| Interest Expense | -295.67 | -300.79 | -315.46 | -423.44 | -323.41 | -320.21 | Upgrade
|
| Interest & Investment Income | 1,130 | 1,431 | 1,477 | 763.35 | 306.23 | 357.47 | Upgrade
|
| Currency Exchange Gain (Loss) | -3,521 | 286.56 | 996.94 | 3,177 | 3,700 | -2,460 | Upgrade
|
| Other Non Operating Income (Expenses) | -1,165 | -1,180 | -157.21 | -1,410 | 90.67 | 57.43 | Upgrade
|
| EBT Excluding Unusual Items | -17,604 | -14,062 | -12,488 | -21,225 | -13,025 | -9,895 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 26.76 | Upgrade
|
| Gain (Loss) on Sale of Assets | -440.02 | -471.69 | 7.35 | 8.99 | -1.08 | -23.92 | Upgrade
|
| Asset Writedown | - | - | - | -14,694 | - | -2,944 | Upgrade
|
| Pretax Income | -18,044 | -14,534 | -12,480 | -35,910 | -13,026 | -12,836 | Upgrade
|
| Income Tax Expense | 4,814 | 4,943 | 248.07 | 388.23 | 577.06 | 1,036 | Upgrade
|
| Earnings From Continuing Operations | -22,858 | -19,477 | -12,728 | -36,298 | -13,603 | -13,873 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | 43.53 | Upgrade
|
| Net Income | -22,858 | -19,477 | -12,728 | -36,298 | -13,603 | -13,829 | Upgrade
|
| Net Income to Common | -22,858 | -19,477 | -12,728 | -36,298 | -13,603 | -13,829 | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 28 | 27 | 27 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 28 | 27 | 27 | 26 | Upgrade
|
| Shares Change (YoY) | 3.15% | 5.62% | 5.63% | 0.17% | 2.63% | 0.11% | Upgrade
|
| EPS (Basic) | -764.29 | -653.04 | -450.74 | -1357.81 | -509.70 | -531.83 | Upgrade
|
| EPS (Diluted) | -764.29 | -653.04 | -451.00 | -1358.00 | -510.00 | -531.99 | Upgrade
|
| Free Cash Flow | -20,999 | -19,080 | -11,553 | -12,842 | -15,429 | -8,151 | Upgrade
|
| Free Cash Flow Per Share | -702.12 | -639.74 | -409.10 | -480.39 | -578.14 | -313.46 | Upgrade
|
| Gross Margin | 21.10% | 22.18% | 12.25% | -1.02% | 13.88% | 25.98% | Upgrade
|
| Operating Margin | -163.57% | -166.05% | -45.67% | -75.93% | -63.02% | -26.30% | Upgrade
|
| Profit Margin | -271.89% | -226.17% | -40.13% | -118.13% | -51.03% | -48.30% | Upgrade
|
| Free Cash Flow Margin | -249.78% | -221.56% | -36.42% | -41.80% | -57.89% | -28.47% | Upgrade
|
| EBITDA | -12,785 | -13,342 | -12,942 | -21,673 | -15,212 | -6,098 | Upgrade
|
| EBITDA Margin | -152.07% | -154.93% | -40.80% | -70.54% | -57.07% | -21.30% | Upgrade
|
| D&A For EBITDA | 966.7 | 957.8 | 1,546 | 1,658 | 1,586 | 1,432 | Upgrade
|
| EBIT | -13,752 | -14,300 | -14,489 | -23,331 | -16,798 | -7,531 | Upgrade
|
| EBIT Margin | -163.57% | -166.05% | -45.67% | -75.93% | -63.02% | -26.30% | Upgrade
|
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.